Uncategorized
NILOTINIB UPDATE: WHERE WE STAND WITH A CANCER DRUG FOR PARKINSON’S
Today MJFF, the Van Andel Research Institute and the Cure Parkinson’s Trust announced plans to collaborate to assess the clinical use and development of cancer drug nilotinib.
Leave a reply